• Former head of psychiatry products at FDA joins Cybin team.
• Laughren will help company plot its regulatory pathway as it studies and develops psychedelic medicines.

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, is making strategic moves as it progresses with pre-clinical and clinical trials. One of those steps includes the company’s recent announcement that Thomas Laughren is joining Cybin’s clinical advisory board (https://ibn.fm/q0abz). A medical doctor who served as the director of the U.S. Food and Drug Administration’s division of psychiatry products for nearly three decades, Laughren will help the company plot its regulatory pathway as it studies and develops psychedelic medicines, says Alex Belser, Cybin’s chief clinical officer. “Psychedelic medicines don’t fit neatly into the old models for how drugs are studied, reviewed and approved,” says Belser. “We brought together experts to help us work within existing clinical and regulatory frameworks while realizing that psychedelics require innovative methods and a new approach.” During his tenure at the FDA, Laughren supervised the research and review of all new psychiatric drug applications and development projects in clinical testing. In addition, he assisted in the design and interpretation of clinical trials for psychiatric drugs. Laughren left the FDA in 2021 to start his own consulting company and has spent the last decade helping psychiatric pharmaceutical drug makers gain FDA approval for new drugs. Cybin CEO Doug Drysdale notes that Laughren’s FDA experience is invaluable as the company moves into the “next chapter” with studies on psilocybin, the psychedelic compound found in “magic” mushrooms. “Building and maintaining strong relationships and communications channels with regulators will be important for Cybin as their understanding of psychedelic therapeutics evolves over time,” says Drysdale. Although Cybin is currently conducting studies on psilocybin, the company is also developing novel molecules based on other psychedelic compounds. In fact, the company has 13 provisional patent applications filed for novel psychedelic molecules. Cybin, a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• AmpliTech Group, a designer and developer of technology that enhances radio frequency (“RF”) transmissions for satellites, 5G, IoT and other applications recently reported record order bookings and orders in progress under deadline
• Thaw in COVID pandemic’s business impact is very encouraging for future business opportunities
• Products serve satellite communications, space, telecommunications (5G/6G) and military defense markets
• Recapitalized and listed on Nasdaq to support variety of growth opportunities
• Cash position of approximately $30M – with no debt

Radio Frequency component designer and manufacturer AmpliTech Group (NASDAQ: AMPG) recently reported record bookings and a record backlog (defined as contractually obligated purchase orders with a deadline for delivery) of $2.4M in conjunction with Q1 results. The New York-based company has delivered industry standard quality products for leaders in satellite communications, space, telecommunications (5G/6G) and military defense markets for nearly 20 years. The company netted ~$30M in cash and began trading on the Nasdaq capital market earlier this year. CEO & CTO Fawad Maqbool expects growing business activity and customer demand from mass reopening of its market segments with steady decline in COVID-19 pandemic impact on customer activity and ramping of company’s business development efforts. “We expect the reopening to benefit AmpliTech going forward, along with potential pent-up demand for solutions in 5G, satellite, cyber security, quantum computing and other markets that have developed over the past year,” Maqbool stated in the Q1 release (https://ibn.fm/dpLQw). “To support the substantial opportunities we have identified, we completed a recapitalization of our company over the first four months of 2021, providing over $30M in current funding to support our growth and demonstrate financial strength to our customers and partners. Additionally, we also up-listed our common stock to Nasdaq to position our company for greater visibility, liquidity and access to a much broader pool of potential investors.” AmpliTech’s Q1 release reports that it achieved design wins reflecting its low noise amplifier (“LNA”) products’ performance, durability, and heat dissipation. It also established a premier on-site testing laboratory enabling it to test its products under extreme temperatures and other conditions to ensure product quality and reduce variable testing costs. Additionally, to address ever increasing security concerns in the communications space, AmpliTech has begun development of an enhanced solution incorporating hardware encryption into its signal amplifiers. These efforts aim to provide secure hardware chip-based encryption to secure 5G network transfer without negatively impacting data speeds and to support increasing IoT (Internet of Things) device adoption. While the LNA products provide significant value and return on investment for satellite network applications in space, AmpliTech sees other exciting applications. Recently, AmpliTech received a developmental order for a special cryogenic-cooled probe head used to facilitate studies on materials, molecules and drugs to treat diseases (https://ibn.fm/6JcA0). The company is well-positioned to expand its market reach given the industry leading quality and performance of its amplifiers. AmpliTech believes the market need for its solutions should grow as the demand for higher fidelity wireless communication systems increases at an exponential rate. The overall market for RF components was valued at $23.79 billion last year and is expected to grow at a compound annual growth rate of 14% through 2025, according to market analysts at Grand View Research (https://ibn.fm/tjvXK). For more information, visit the company’s website at www.AmpliTechInc.com. NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at https://ibn.fm/AMPG

• Science continues to substantiate use of cannabis for pain relief, epileptic seizure control
• Research suggests strains with optimized cannabinoid profiles are more effective
• PACR produces premium top-quality strains cultivated using genetics-first approach to optimize cannabinoid profiles
• Genetic cultivation techniques allow selection for specific growing environments, maximum yields

With a growing list of use cases spanning pain relief to seizure control, the medicinal use of cannabis goes back thousands of years (https://ibn.fm/X68wD). Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM), a Canadian cannabis company, leverages a genetics-focused approach to producing premium-quality strains with optimum cannabinoid profiles that are prized among consumers, including those in the hyper-growth medicinal space. Recent studies suggest that tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”), along with hundreds of other potentially active compounds, can help relieve pain and control seizures. Referred to as “full-spectrum” cannabis, these specialized strains with optimized profiles were shown to be more effective due to the synergistic effect between specific cannabinoids and terpenes, organic compounds that enhance the effect of cannabis. Pac Roots leverages high-end genetics and specialized cultivars to produce distinctive cannabis products, specifically strains that can be tailored for medicinal purposes. This is made possible through Pac Roots’ exclusive partnership with Phenome One, a plant breeding management and analytics firm that gives the Company access to one of the largest live genetic libraries in Canada. Through Phenome One’s platform, Pac Roots has access to a massive database detailing over 350 unique laboratory-analyzed and rigorously field-tested cannabis cultivars that support each stage of the breeding process. Supported by data going back over 30 years, Pac Roots is also able to produce top-quality anti-fungal strains that are bred to thrive in specific climates – including the Fraser Valley in British Columbia where the Company recently made a sizeable land purchase. With its high-quality soil and favorable climate, the Fraser Valley Regional District is known worldwide as one of Canada’s most productive and intensively farmed areas. Pac Roots recently made the strategic purchase through a share purchase agreement that gave the Company outright ownership of 250 acres of land spread over nine parcels. “The addition of such a substantial package of land to our portfolio is a major step for PacRoots. We are pleased to have the opportunity to add significant acreage with an acquisitional cost base of $9,600 per acre,” said Pac Roots President and CEO Patrick Elliott (https://ibn.fm/0cuZr). “This land has no zoning restrictions and is not situated within the Agricultural Land Reserve, which provides for infinite development possibilities.” Medicinal cannabis products are growing in popularity across all demographics because of increased consumer awareness and the growing body of scientific evidence. As consumer demand for medicinal cannabis increases, the ability to deliver top-quality strains with optimized cannabinoid profiles is growing in importance. Pac Roots’ novel genetics-based approach to producing premium-grade cannabis, along with its portfolio of pristine land and production assets, is positioning the company favorably as a leader in the rapidly growing industry. For more information, visit the company’s website at www.PacRoots.ca. NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• The Mobius Interactive flagship brand, Mobius.bet, is a top sponsor for the next six matches of the 2021 FIFA World Cup Soccer Qualifiers in Brazil
• The Mobius.bet brand will be showcased on Globo TV Brazil, attracting 35 – 40 million viewers per match
• By partnering with Globo TV, Mobius Interactive will reach more sports enthusiasts, showcasing the Mobius.bet brand and growing its market reach

Mobius Interactive has signed a lucrative sponsorship agreement to display its flagship brand, Mobius.bet, on national TV in Brazil for the 2021 FIFA World Cup Qualifiers, marking the company’s entry into the expanding Brazilian iGaming industry. Mobius Interactive has burst onto the scene of this booming market with its main brand, Mobius.bet – based upon research and knowledge of the region.This strategic move will capitalize on the current surge in Latin America’s iGaming and Esports markets. This iGaming industry is projected to grow at a CAGR of 11.4% between 2018 and 2023, ultimately posting total revenues of $6.29 billion. This venture into the Brazilian market is well-calculated and perfectly-timed. Mobius Interactive is pulling out all the stops in Brazil, getting in early to capitalize on this situational opportunity with tremendous growth potential. The agreement to display Mobius.bet ads on Brazilian national TV opens a new front in Mobius Interactive’s campaign to conquer the lucrative Latin American gaming market. With Globo TV, Brazil’s largest television station, Mobius Interactive is able to reach 99.5% of the country’s population of 211 million. Mobius Interactive’s partnership with Globo TV presents the ideal opportunity take full advantage of this market—a market set for exponential growth. It is estimated that the Brazil World Cup qualifiers will attract about 35 million viewers per match on Globo TV. The highly-anticipated game between Brazil and its archrival, Argentina, is projected to attract about 40 million viewers. Mobius Interactive is capitalizing on these impressive numbers to push its brand in the Latin American market, taking full advantage of this vast audience and the football culture of Brazil, a soccer powerhouse with more World Cup victories than any other team in history. The matches:

• Chile vs Brazil (2nd September)
• Brazil vs Peru (7th September)
• Venezuela vs Brazil (7th October)
• Brazil vs Uruguay (12th October)
• Brazil vs Colombia (11th November)
• Argentina vs Brazil (16th November)

Mobius Interactive is open for investment opportunities. For further information please contact: Gary Eldridge – President 1 (604) 783-1685  gary@mobiusinteractive.ltd Seamus Byrne – VP Corporate Development 1 (902) 441-5757  seamus.byrne@halifaxcitrus.ca Tracey Miller – VP Mergers & Acquisitions 1 (604) 355-5589  tracey@mobiusinteractive.ltd  For more information, visit the company’s website at www.MobiusInteractive.Ltd. NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• XPhyto partners with AGORA t to grow its brand and overall market share
• The agreement entails shares issued to AGORA on August 21, 2021 and December 31, 2021 at a price of $2.12 per share, subject to a hold period that ends on October 18, 2021
• AGORA is known for its online marketing, conferences, broadcasting and investor relations services
• Its clients include CardioComm Solutions, Good Life Networks, Northern Sphere, Grizzly Discoveries and IntellaEquity Inc., among others

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) just announced that it is following through with its advertising agreement with AGORA Internet Relations Corp (“AGORA”) that dates back to December 1, 2020. The agreement entails shares issued to AGORA on August 21, 2021 and December 31, 2021 at a price of $2.12 per share, subject to a hold period that ends on October 18, 2021 with respect to the various applicable securities legislation. With this move, AGORA now holds 20,549 common shares of XPhyto, equivalent to 0.03% of the issued and outstanding common shares (https://ibn.fm/GVoHm). AGORA is known for its online marketing, conferences, broadcasting and investor relations services for the global market. With its online community, AGORA is able to help investors and small companies to not only discuss but also discover small cap stocks and investment opportunities (https://ibn.fm/BgDHx). Its client list is constantly growing and is currently made up of companies such CardioComm Solutions, Good Life Networks, Northern Sphere, Grizzly Discoveries and IntellaEquity Inc., among others (https://ibn.fm/cuUyv). XPhyto plans on capitalizing on the experience that AGORA has by working with the other clients and leveraging on this to grow its brand and overall market share. XPhyto is a life sciences technology accelerator, focusing on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. Its biggest achievement so far has been its rapid COVID-19 PCR test kit that reduces test turnaround times to less than 30 minutes (https://ibn.fm/KELop). The company has operations in Europe and North America, with an operational focus in Germany. This partnership with AGORA has the potential to push the XPhyto brand even further, allowing it to appeal to more customers and fulfil its agenda for growth and commercialization for the European market. For more information, visit the company’s website at www.XPhyto.com. NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

• FingerMotion’s strategy is to rapidly expand its user base through organic means utilizing a broad range of innovative applications
• It handles over 500,000 transactions every day for its mobile payment and recharge service, all facilitated by superior technology
• Technology and innovation are at the center of FingerMotion’s operations and activities and will clearly play a significant role in the company’s future

FingerMotion (OTCQX: FNGR), since its inception back in 2016, has always pushed boundaries with innovation and introducing new ideas. Innovation has always played a central role in what the company does, and it leverages this to expand its market reach and grow market share. The company’s core competencies are mobile payments and recharge platform solutions for the Chinese market (https://ibn.fm/CSTyS). Today, it serves over a billion users in this market, intending to expand to other regions in the future. In 2021 alone, the company has introduced innovative insurance applications collaborating with Xunlian Tanxia Technology and Happy Life Insurance (https://ibn.fm/XIUKB). This innovation trend extends onto its other product offerings that fall into three main categories: Telecommunications Products and Services, SMS and MMS Services, Big Data Insights, and the Rich Communication Services (“RCS”) platform. FingerMotion’s vision is to continue growing its user base, mainly through organic means. It also seeks to leverage this growth and transform it into an ecosystem of users with high engagement rates while utilizing its broad range of innovative applications (https://ibn.fm/w2wNR). So far, the company handles over 500,000 transactions every day for its mobile payment and recharge service (https://ibn.fm/rgfus). These milestones have been achieved through the company’s technology and innovation, and the company seeks to develop further value-added technologies targeting its customer base. FingerMotion’s innovation cuts across its four pillars of growth. These include its flourishing SMS business, strong top-up, mobile recharge business, emerging portal sales, and Insuretech space (https://ibn.fm/pngrc). The company has made incredible strides, with key achievements and milestones that include the launch of its Sapientus offering that capitalizes on big data and market-forming technology. Additionally, FingerMotion has also been responsible for launching business with the three key eCommerce portals in China – JD.com, PinDuoDuo and Alibaba (https://ibn.fm/E1szq). Additionally, the two are intended to play a vital role in the company’s future, especially regarding taking over the Chinese market and expanding to other regions. Also, the company has been very vocal about outpacing changes in technology, which is integral given how fast technology is changing and the potential that it holds in FingerMotion’s market. Technology affects how people learn, think, communicate, conduct business, or even interact with each other. FingerMotion’s move to bank on technology leverages the potential that it has and a consumer base committed to utilizing technology to make their lives easier. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• CYBN subsidiary Adelia Therapeutics has reached earn-out milestones.
• Adelia’s earn-out milestones contributed to positive preclinical results with multiple proprietary psychedelic molecules.
• Cybin’s development of these compounds differentiates it from companies focused on naturally occurring psychedelic compounds.

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that earn-out milestones have been reached by its wholly controlled subsidiary Adelia Therapeutics Inc. These milestones, which were for the period commencing Jan. 1, 2021, add value to Cybin’s pipeline of novel psychedelic compounds (https://ibn.fm/Y1YPb). “These positive catalysts continue to provide the necessary data required to demonstrate that Cybin’s proprietary deuterated psychedelic molecules potentially carry the same pharmacodynamic properties, safety profiles, potency and receptor targeting as their parent molecules,” said Cybin CEO Doug Drysdale. “While the profiles are similar to parent molecules, early research has shown that these proprietary molecules also carry certain characteristics that may lead them to potentially become commercially viable because of their improved stability, bioavailability, controlled psychedelic duration and overall enhanced chemical make-up.” Adelia’s earn-out milestones contributed to positive preclinical results with multiple proprietary psychedelic molecules, the company reported. Those results determined that proprietary deuteration modifications in multiple-lead new chemical entity candidates did not alter pharmacodynamic properties and did not alter safety as assessed in in-vitro toxicity tests as compared to non-deuterated analogs. These promising results add value to the pipeline of proprietary novel psychedelic compounds that Cybin is developing. The results, the company noted, demonstrate that “these molecules perform similarly to the naturally occurring molecules in certain important metrics. The development of these compounds differentiates Cybin from companies focused on naturally occurring psychedelic compounds.” Cybin closed on its acquisition of Adelia in December 2020 in a move that Drysdale stated as “potentially advancing Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder. “Adelia’s focuses on novel delivery methods and innovative therapies may contribute to our goal of therapies with faster onset of action, smoother pharmacokinetic profiles, shorter treatment periods and reduced side effects,” Drysdale continued. “Adelia’s expertise across multiple molecules and multiple indications could potentially give Cybin the ability to address gaps across a larger domain” (https://ibn.fm/XaFk4). Cybin, a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• PlantX Life recently launched as a seller on both Walmart Canada Marketplace and Hudson’s Bay Marketplace
• The launches appear to be leveraging the changes and trends brought about by the COVID-19 pandemic
• In addition, the agreements are part of PlantX’s growth strategy
• The company will offer thousands of its products on both platforms

As the COVID-19 pandemic upended multiple aspects of life in Canada, it did not spare the retail industry. Here, it forced Canadians to rethink how, where and when they shop, with the paramount consideration in their decision-making process being their personal and family health and safety. Shopping was no longer about what was trendy, cheap or convenient, but how safe it was. This shift instigated a dramatic drop in the number of in-store visits, even for groceries, with shoppers instead opting to go digital. According to a study by KPMG Canada, 66% of Canadians increased their online shopping habits as a result of the pandemic. The 47% of Canadians who shifted to e-commerce do not miss their old way of grocery shopping, while only 15% of Canadians miss their old shopping habits and are eager to return to them (https://ibn.fm/4OX3F). The overall result was that online retail as a share of total retail sales grew from 3.6% in 2019 to 6.2% in 2020 (https://ibn.fm/cqWnH). These trends benefited some e-commerce stores, including Walmart Canada Marketplace, whose e-commerce sales grew by a staggering 229% during the pandemic. In a deal that will allow it to leverage these trends/statistics, as well as Walmart Canada Marketplace’s extensive digital marketing services and customer base, PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) launched as a seller on Walmart Canada Marketplace, fulfilling a June 1 announcement. As part of the new collaboration, PlantX will make available for sell plant-based household supplies and pantry items from various brands, including Made in Nature, Cadia, Chickapea, NuNaturals, Fody, Plant Snacks, and Quantum, with potential opportunities to diversify its offerings on the platform in future (https://ibn.fm/vQ9xo). “We have been focused on executing our growth strategy and our products being added to Walmart Marketplace is another component of expansion efforts,” commented PlantX Founder Sean Dollinger. “With our profile as a seller on this platform now active, we are excited to continue expanding access to our products to customers in Canada.” In the June 1 communique (https://ibn.fm/fiph1), Dollinger had stated that the collaboration demonstrates the demand for PlantX’s products and “redefines PlantX’s potential as a plant-based leader.” The Walmart Canada Marketplace announcement followed on the heels of a May 25 announcement that PlantX had launched as a seller on Hudson’s Bay Marketplace, a diversified retailer. While browsing the online store, customers can expect to find an assortment of indoor live plants, Nootka & Sea’s cosmetics and personal care products, and plant-based pet food from brands such as Evolution Diet and Benevo. Eventually, PlantX intends to offer more than 2,000 products on this online marketplace (https://ibn.fm/F2AfQ). “Witnessing our agreement with Hudson’s Bay Marketplace come to life is beyond encouraging,” stated PlantX CEO Julia Frank. “We hope practical ramifications of these efforts will be tangible, and we are looking forward to working with Hudson’s Bay Marketplace.” With the majority of Canadians having already shifted to online shopping and an equally large proportion stating that they will continue going down that road well into the future, PlantX strategic partnerships appear to be capitalizing on the changes and emerging trends in the food and beverage industry. Vancouver-based PlantX Life is a high-growth technology company focused on consumer-packaged goods (“CPG”) for the plant-based community. The company is committed to educating and empowering those interested in a plant-based lifestyle. “Shop with confidence at Plant X,” reads the company’s website. “We’ve done the work for you and everything we endorse meets our guideline for personal health and wellness morals. If it isn’t plant-based, we don’t offer it.” For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://Investor.PlantX.com/ and view PlantX for Plant-Based Investors. To visit the company’s YouTube channel, click here (https://ibn.fm/XiCLc). NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• GTVH, HyFrontier Technologies working together to offer a patent-pending hydrogen and oxygen delivery system for agriculture.
• Company has seen recent developments that could significantly benefit the entire agricultural industry.
• Duplicating enhanced-growth thunderstorms cause can reduce need for crop rotations, helping millions of people avoid starvation.

A little more than a month after announcing its formal purchase agreement with HyFrontier Technologies (https://ibn.fm/RZkbo), Golden Triangle Ventures (OTC: GTVH) is making good on its commitment to pursue ventures in the technology sector to provide advanced technology for the modern era. GTVH and HyFrontier Technologies are working together to offer a patent-pending, first-of-its-kind hydrogen and oxygen delivery system for agriculture (https://ibn.fm/4jSkX). “This acquisition has been something [we] have been working towards for quite some time,” said Golden Triangle Ventures CEO Steffan Dalsgaard, upon announcing the purchase agreement. “We knew that completing this agreement would show the world that we are fully committed to both our shareholders and the brilliant future of this revolutionary company. . . . In just the past few weeks, there have been developments that could significantly benefit the entire agricultural industry, which have only further bolstered my confidence on the trajectory and path forward.” The mission of HyFrontier Tech is to improve global crop-production efficiency. To do this, the company is developing HyGrO, its patent-pending process and device technology, based on the understanding that lightning and thunderstorms deliver nitrogen and hydrogen to the soil, resulting in enhanced growth. In-house testing shows that hydrogen is capable of increasing crop yields by up to 25% and, in many circumstances, much higher. Larger root systems and better overall plant health were also observed in plants watered with the HyGrO unit. “A bolt of lightning is so powerful, it breaks the covalent bonds of both the air and water it makes contact with to create nitrogen, oxygen and hydrogen, which gets caught up in the rain and downdraft of the storm, falling to the earth, providing critical nutrients plants need,” the company explains. GTVH and HyFrontier believe that duplicating the enhanced growth thunderstorms cause can become a reality, thereby reducing the need for crop rotations and helping millions of people avoid starvation. “Land will yield better results for future generations,” the company continued, “paving the way for a more sustainable future.” HyGrO can be used on any species of plant life in nearly any grow medium; it can also be retrofitted to wellheads for large-scale agricultural projects, indoor grow operations and small farms or utilized for a multitude of residential home and garden applications. Currently, HyFrontier is working with several universities to validate the HyGrO technology, with preliminary indications showing extremely positive results. Golden Triangle Ventures is a multifaceted consulting company with many projects being developed that provide synergistic values in the health, entertainment and technology industries. The company aims to purchase, acquire and/or joint venture with established entities that management can help assist and develop into unique opportunities. Additionally, GTVH provides a professional corporate representation service to different companies in these sectors while consulting on a variety of business-development objectives. The goods and services represented are driven by innovators who have passion for and commitment to these marketplaces. The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. For more information, visit the company’s website at www.GoldenTriangleInc.com. NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://ibn.fm/GTVH

• The program’s initial focus is to support those at risk or already diagnosed with diabetes or cardiovascular disease, offering better health management and quality of life
• In the United States, approximately 88 million adults live with prediabetes, and as many as 84% do not know they have it. It is estimated that by 2030, 13.6 million Canadians will be diabetic or prediabetic
• The global point-of-care diagnostics testing market was valued at $30.45 billion in 2021 and is anticipated to grow at a CAGR of 3.25%, resulting in a revenue forecast of $35.74 billion by 2028

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF), a pharmacy service innovator focused on the acquisition and development of early-stage technologies, has reported success in the pilot rollout for Shoppers Drug Mart(R) and the company’s wholly owned subsidiary HealthTab(TM). HealthTab(TM) is a turnkey point-of-care testing solution for pharmacies to provide a larger role in primary care delivery, which empowers patients to take control of their health (https://ibn.fm/9K873). Avricore Health’s CEO, Hector Bremner, and key team members will conduct regular investor calls to provide progress updates and take questions about the innovative solution and the rollout program. In the first such investor call, which took place July 6, the agenda included opening remarks, team introduction, presentation, updates, and a 30-minute Q&A session. “We have many enthusiastic supporters, and we want to be able to provide a forum to share more insights on our plans and progress. I’m looking forward to taking questions and keeping a regular dialogue going about how we are changing the face of rapid-diagnostics in pharmacy,” Bremner commented (https://ibn.fm/S3DDU). The call came just after the initial systems testing was completed on HealthTab(TM), demonstrating that it was operating successfully after implementation in the first 11 Shoppers Drug Mart locations where it was launched. The rollout is a part of the Master Agreement and Statement of Work. Under this agreement, the initial Ontario locations receive the point-of-care testing platform from HealthTab(TM) that features the Afinion2(TM) blood chemistry analyzers by Abbott Rapid Diagnostics. The program’s initial focus is to screen patients at risk or already diagnosed with diabetes and cardiovascular disease, offering a better way to manage the conditions for a higher quality of life. As key milestones are accomplished, the company will add more locations to the HealthTab(TM) network, further expanding per the Master Agreement with Shoppers Drug Mart Canada. The screening program is an innovative and convenient solution for potentially millions of people with prediabetes or diabetes, a massive market that is constantly expanding. It is estimated that in the United States, there are approximately 88 million adults (more than 1 in 3) living with prediabetes (https://ibn.fm/42OtS). Of these 88 million, more than 84% of them don’t know that they have it. Nearly 13.6 million Canadians are expected to be diabetic or prediabetic by 2030, with many being underdiagnosed (https://ibn.fm/7eHCz). Prediabetes increases the risk of developing Type 2 diabetes, stroke, and heart disease. Additionally, a successful rollout of the HealthTab(TM) platform will help position Avricore Health as a leading company in the point-of-care diagnostics and testing market, which is anticipated to gain momentum in the coming years. The global market was valued at $27.8 billion in 2020 and increased to $30.45 billion in 2021 (https://ibn.fm/8KVTn). Expected to grow at a CAGR of 3.25% from 2021 to 2028, the revenue forecast for 2028 is $35.74 billion. North America was the largest regional market in 2020, accounting for over 34% of the revenue, and is expected to maintain its position throughout the forecasted years. In terms of clinics, pharmacies and retail clinics showed higher use of point-of-care diagnostic systems, followed by physician offices. For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF